BridgeBio Pharma, Inc. Common Stock (BBIO) Valuation
Historical valuation analysis based on 500 data points (2024-09-23 to 2026-09-21)
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs i...
BridgeBio Pharma, Inc. Common Stock (BBIO) currently trades at a P/S ratio of 22.36 (range: 21.46–70.27, 2th percentile — cheap relative to its history).
BridgeBio Pharma, Inc. Common Stock appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 22.36 | 21.46 | 33.44 | 70.27 | 2th | cheap relative to its history |
BridgeBio Pharma, Inc. Common Stock (BBIO) Valuation & P/E History
BridgeBio Pharma, Inc. Common Stock (BBIO) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $66.75 with a market capitalization of $13.1 billion. This page provides historical valuation analysis for BBIO based on 500 data points covering 2024-09-23 to 2026-09-21.. The P/S ratio of 22.36 compares to a median of 33.44.
BBIO Valuation Metrics & Historical Range
The valuation table above shows BridgeBio Pharma, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BBIO is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BBIO is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for BridgeBio Pharma, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BBIO Overvalued or Undervalued?
BridgeBio Pharma, Inc. Common Stock appears significantly undervalued relative to its historical range, trading at depressed multiples across most metrics. The overall valuation percentile of 2 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BBIO is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BBIO analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BBIO trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.